Takeshi Imaoka
Kobe, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme).
Journal: Diabetes, obesity & metabolism
Published: October 20, 2022
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.
Journal: The lancet. Diabetes & endocrinology
Published: March 03, 2022
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.
Journal: The lancet. Diabetes & endocrinology
Published: March 03, 2022
Multinational Observational Study to Understand Insulin Treatment Intensification: Japanese Subgroup Analysis of the MOSAIc Study.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: September 02, 2021
A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.
Journal: Diabetes, obesity & metabolism
Published: July 07, 2021
Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: August 17, 2020
Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study.
Journal: Current medical research and opinion
Published: April 10, 2020
Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog® in Japanese Patients with Type 1 Diabetes: PRONTO-T1D Subpopulation Analysis.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: March 27, 2020
Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog® in Japanese Patients With Type 2 Diabetes: PRONTO-T2D Subpopulation Analysis.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: March 27, 2020
Open-label, randomized study comparing basal insulin peglispro and insulin glargine, in combination with oral antihyperglycemic medications, in insulin-naïve Asian patients with type 2 diabetes.
Journal: Journal of diabetes investigation
Published: November 14, 2016
A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial.
Journal: Endocrine journal
Published: October 20, 2015
Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.
Journal: Diabetes, obesity & metabolism
Published: August 27, 2015
Last Updated: 09/26/2026